Compare › Ozempic vs Zepbound
Ozempic vs Zepbound
Ozempic is semaglutide; Zepbound is tirzepatide. Different molecules, different sponsors, separate FDA applications. What follows is what the public record holds on each.
| Ozempic | Zepbound | |
|---|---|---|
| Active ingredient | semaglutide | tirzepatide |
| FDA application | NDA209637, NDA213051 | NDA217806 |
| First FDA action | 2017-12-05 | 2023-11-08 |
| Sponsor | Novo Nordisk | Eli Lilly |
| EU authorisation | Ozempic | Not under this name |
| FDA supply status | No open records | No open records |
| FDA actions on file | 28 | 45 |
| Active trials of the molecule | 203 | 99 |
Everything above is a field from Drugs@FDA, the FDA Drug Shortage Database, the EMA register or ClinicalTrials.gov. There is no efficacy comparison here and there will not be one: head-to-head claims belong to the trials that made them, and which drug suits a particular person is a question for a clinician.
Full records: Ozempic · Zepbound · semaglutide · tirzepatide